Pantorc (Pantoprazole)

Pantoprazole is a proton pump inhibitor that acts on the acid‑secretion pathway of the stomach. It is used for several gastrointestinal indications:

• Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Erosive oesophageal ulcer: accelerates healing of ulcerated tissue in the oesophagus.
• Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the disorder.
• NSA‑related ulcer prophylaxis: lowers the risk of ulcer development in patients taking long‑term non‑steroidal anti‑inflammatory drugs.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding covalently to the pump’s cysteine residues, it blocks the final step of acid production, leading to a sustained increase in gastric pH and reduced acidity in the stomach.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea or abdominal discomfort.
• Flatulence or bloating.
• Constipation: occasional.
• Dry mouth.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis, angioedema).
• Clostridioides difficile‑associated colitis.
• Acute interstitial nephritis.
• Low magnesium levels (hypomagnesemia) with prolonged use.
• Fracture risk with long‑term high‑dose therapy.
• Liver enzyme elevations indicating possible hepatic injury.

When prescribing Pantorc, clinicians should consider several safety aspects:

• Renal impairment: adjust dose in severe renal dysfunction.
• Hepatic impairment: use with caution in moderate to severe liver disease.
• Elderly patients: monitor for bone‑density loss and electrolyte disturbances.
• Long‑term therapy: assess need for periodic vitamin B12 and magnesium monitoring.
• Drug‑interaction potential: review concomitant medications for CYP2C19 substrates.
• Store at ambient temperature: keep below 25 °C, protect from moisture and keep in the original packaging.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH.
• HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.
• Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR; monitor coagulation.
• Digoxin: slight increase in serum levels.
• Methotrexate (high‑dose): reduced renal clearance; monitor renal function.
• Oral contraceptives: potential decrease in efficacy; advise backup contraception.